In Vivo Assessment of Clinical Performances of Commercially Available Synthetic Osteoconductive Grafts B-OSTIN HA Nano™ and OSferion™ During Direct Sinus Lift Surgical Procedures for Managing Inadequate Implant Bone Heights in Middle-Aged Patients: A Hosp

Abstract

Aim: This study aims to assess the clinical performance of commercially available, specific, synthetic, Osteoconductive and Biocompatible Grafts B-OSTIN HA Nano™ and OSferion™ during the Direct Sinus Lift procedure for managing inadequate Implant Bone heights in middle-aged patients

Materials and Methods: This study includes a total of 30 patients with a missing Maxillary Right Molar. Inclusion criteria required ages 35-60 and excluded those with systemic diseases, mental instability, or smokers. Significant bone resorption was noted on Cone Beam Computed Tomography (CBCT), necessitating a maxillary sinus lift. During surgery, a flap exposed the sinus's anterior wall, and graft material was packed into the sinus using the "Postage Stamp Technique." Three months later, implants were placed, with healing abutments and implant-supported prostheses installed. Patients were divided into two groups: Group 1 received Hydroxyapatite (B-OSTIN HA Nano™) grafts and Group 2 received Tricalcium Phosphate (OSferion™) grafts. Clinical parameters, including bone height increase and graft stability, were evaluated with CBCT, assessing implant stability as satisfactory, non-satisfactory, questionable, or hopeless. This study aims to evaluate the clinical performance of the grafts during sinus lift procedures for inadequate implant bone heights.

Statistical Analysis and Results: This study involved 30 patients aged 35 to 60 years, missing the maxillary right first molar and seeking implant placement. Cone-Beam Computed Tomography (CBCT) scans indicated reduced bone height, necessitating a maxillary sinus lift and alloplastic bone grafts. Implants were placed three months after the lift, with prosthesis fitting three months later. Patients were divided into two groups: Group 1 received Hydroxyapatite (B-OSTIN HA Nano™) grafts, while Group 2 received Tricalcium Phosphate (OSferion™) grafts. CBCT evaluations showed that Group 1 had 9 patients with satisfactory bone height increases, 8 with satisfactory scaffold responses, and 7 with satisfactory implant stability. In Group 2, 8 had satisfactory increases in bone height, 7 had scaffold responses, and 6 had implant stability. Group 1 outperformed Group 2 overall, as detailed in statistical analyses using one-way ANOVA.

Conclusion: This study concluded that Hydroxyapatite (B-OSTIN HA Nano™) significantly improves bone height compared to Tricalcium Phosphate (OSferion™), which is essential for successful implant placement. Hydroxyapatite serves as an effective scaffold for new bone tissue growth and is praised for its biocompatibility, while Tricalcium Phosphate is favoured for its biodegradability and rapid regeneration. Further research is needed to compare the efficacy of these materials.